Uni-Bio Science Group Ltd. (0690) AI Stock Analysis

• Market Cap: HK$643.37M
• Dividend Yield: 2.37%
• Average Volume (3M): 5.61M
• Price to Earnings (P/E): 2.2
• Beta (1Y): -0.05
• Revenue Growth: 15.97%
• EPS Growth: -3.77%
• Country: HK
• Employees: 487
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.01
• Shares Outstanding: 5,971,228,000
• 10 Day Avg. Volume: 4,310,360
• 30 Day Avg. Volume: 5,609,336
• PEG Ratio: 0.21
• Price to Book (P/B): 1.13
• Price to Sales (P/S): 0.67
• P/FCF Ratio: 12.83
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 66 Neutral
• Price Target: HK$0.14 ▲(4.62% Upside)
• Action: Reiterated Date: 11/28/25
• Date: Action: Reiterated 11/28/25

The stock score is primarily influenced by strong financial performance and attractive valuation. However, technical indicators suggest bearish momentum, which tempers the overall score. The absence of operating cash flows is a concern that needs monitoring.

Positive Factors

Revenue & margin strength

Sustained double-digit revenue growth alongside very high gross margins and improving EBIT/EBITDA margins indicate durable product economics and pricing power. This supports long-term reinvestment in R&D and commercial expansion and underpins persistent profitability over multiple years.

Conservative capital structure and high ROE

Low leverage and a strong equity ratio provide financial flexibility to fund capex, R&D, or M&A without overreliance on external debt. A 25% ROE signals efficient use of capital, supporting sustainable shareholder returns and the ability to weather industry cycles.

Vertically integrated China-focused pharma model

Control across R&D, manufacturing and commercialization enhances margin capture, supply reliability, and faster product rollout in China. A focused therapeutic franchise supports specialized sales expertise and long-term market penetration in endocrinology, strengthening competitive positioning.

Negative Factors

No operating cash flow in 2024

Reported absence of operating cash flow despite accounting profits suggests weak cash conversion, potential working capital strain, or timing issues. Over months this can pressure liquidity, constrain R&D/capex funding, and force external financing that dilutes financial resilience.

Negative EPS growth

An EPS decline while revenues grow points to margin erosion drivers such as higher operating costs, one-offs, or financing impacts. If persistent, lower earnings per share can limit retained earnings for reinvestment and weaken investor confidence in long-term profit generation.

Geographic and therapeutic concentration risk

Heavy reliance on the China market and a narrow therapeutic focus increases exposure to local regulatory, reimbursement, and competitive shifts. Limited geographic and product diversification can amplify downside from policy changes or demand swings over the medium term.

Uni-Bio Science Group Ltd. Business Overview & Revenue Model

Company Description

Uni-Bio Science Group Ltd. (0690) is a biotechnology company based in Hong Kong, primarily engaged in the research, development, manufacturing, and commercialization of high-quality biopharmaceutical products. The company focuses on the fields of oncology, autoimmune diseases, and other therapeutic areas, providing innovative solutions through its proprietary technologies and product pipelines. Uni-Bio Science is committed to enhancing patient care and improving health outcomes by delivering cutting-edge biopharmaceuticals and engaging in collaborations that expand its market reach.

How the Company Makes Money

Uni-Bio Science Group Ltd. generates revenue through multiple streams, focusing primarily on the sales of its biopharmaceutical products. The company earns income by marketing its proprietary drugs and therapies, particularly in oncology and autoimmune disease treatments, to healthcare providers and institutions. Additionally, Uni-Bio may engage in strategic partnerships and collaborations with other pharmaceutical companies, which can result in milestone payments, royalties based on sales, and co-development agreements. The company also explores licensing its technologies and products to other firms, further diversifying its revenue sources. Research grants and funding from governmental or non-governmental organizations may also contribute to its earnings, especially for ongoing research and development projects.

Uni-Bio Science Group Ltd. Financial Statement Overview

Summary

The income statement shows strong revenue growth and profitability with high margins. The balance sheet is stable with low leverage and strong equity. However, the absence of operating cash flows in 2024 raises concerns about liquidity.

Income Statement

The income statement shows a strong performance with consistent revenue growth, marked at 14.1% from 2023 to 2024, and improving profitability. The gross profit margin is high at 83.4% for 2024, indicating effective cost management. The net profit margin improved to 15.0% in 2024, reflecting increased efficiency. Both EBIT and EBITDA margins have shown positive trends, at 17.4% and 20.5% respectively, up from previous years.

Balance Sheet

The balance sheet reflects a stable financial position with a strong equity base. The debt-to-equity ratio remains low at 0.35, indicating low leverage. The equity ratio is robust at 62.9%, suggesting a healthy capital structure. Return on equity improved to 25.4% in 2024, showcasing efficient use of equity capital. Overall, the balance sheet demonstrates financial stability with potential for growth.

Cash Flow

Cash flow from operations is non-existent in 2024, which may raise concerns about cash generation capabilities. Historically, free cash flow showed positive growth, but recent results are unavailable. The absence of operating and free cash flow data in 2024 suggests a need for cautious monitoring of liquidity and cash management strategies.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	589.59M	552.98M	484.72M	440.32M	353.40M	208.78M
Gross Profit	484.56M	461.07M	392.82M	334.88M	277.01M	181.09M
EBITDA	122.21M	113.56M	93.56M	61.21M	1.31M	-49.95M
Net Income	91.35M	82.77M	70.88M	38.51M	-19.59M	-71.32M
Balance Sheet
Total Assets	556.05M	517.55M	409.99M	292.47M	267.59M	252.72M
Cash, Cash Equivalents and Short-Term Investments	170.51M	183.90M	129.24M	98.22M	83.61M	61.04M
Total Debt	108.00M	115.19M	56.30M	22.67M	5.60M	3.14M
Total Liabilities	173.20M	191.91M	152.82M	97.72M	93.29M	63.31M
Stockholders Equity	382.85M	325.64M	257.17M	194.75M	174.31M	189.41M
Cash Flow
Free Cash Flow	32.93M	28.71M	39.11M	20.23M	3.61M	-28.45M
Operating Cash Flow	70.93M	66.71M	98.85M	48.66M	12.04M	-15.47M
Investing Cash Flow	-45.62M	-168.07M	-76.14M	-27.03M	42.12M	-24.65M
Financing Cash Flow	-26.60M	27.79M	24.51M	2.58M	478.00K	-5.41M

Uni-Bio Science Group Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.13
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0690, the sentiment is Negative. The current price of 0.13 is above the 20-day moving average (MA) of 0.11, above the 50-day MA of 0.12, and above the 200-day MA of 0.12, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.80 is Neutral, neither overbought nor oversold. The STOCH value of 46.99 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0690.

Uni-Bio Science Group Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0690	66 Neutral	HK$643.37M	2.22	26.27%	2.37%	15.97%	-3.77%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
9939	48 Neutral	HK$1.42B	-1.67	-54.87%	―	―	81.67%
2257	44 Neutral	HK$636.90M	-3.65	―	―	―	83.89%
6628	43 Neutral	HK$933.20M	-2.47	-34.18%	―	-57.84%	24.58%
1244	41 Neutral	HK$895.87M	-2.53	-21.45%	―	-8.43%	64.33%
2126	41 Neutral	HK$782.97M	-1.01	-51.56%	―	2.45%	2.58%

Uni-Bio Science Group Ltd. Corporate Events

Uni-Bio Science Strikes Tripartite R&D Pact to Advance Regenerative Medicine Pipeline

Uni-Bio Science Group Limited has signed a tripartite strategic cooperation agreement with the National Engineering Research Center for Cell Growth Factor Drugs and Protein Formulations of Wenzhou Medical University and the Wenzhou Ouhai District People’s Government to deepen collaboration in regenerative medicine. The partners plan to establish a Uni-Bio–WMU joint innovation laboratory for translational medicine, combining research, industrial capabilities and government policy support to develop new growth-factor-based therapies and delivery systems for conditions including NASH, asthma and bone tissue repair. Backed by the China Gene Valley platform and WMU’s globally recognized expertise in cell growth factor drugs, the initiative is expected to boost Uni-Bio’s R&D efficiency, expand clinical applications of its existing products, strengthen its position in the EGF/FGF segment and accelerate commercialization of its innovative pipeline, thereby enhancing its long-term competitiveness and value for shareholders.

The most recent analyst rating on (HK:0690) stock is a Hold with a HK$0.12 price target. To see the full list of analyst forecasts on Uni-Bio Science Group Ltd. stock, see the HK:0690 Stock Forecast page.

Uni-Bio Science Extends Connected Loans to 2027 Under Hong Kong Listing Rules

Uni-Bio Science Group Limited has extended the maturity of existing loans advanced by a wholly owned subsidiary to connected parties Dongguan Taili and Guangzhou Taili from 31 December 2025 to 31 December 2027, under new extension agreements signed on 29 December 2025. The DG Loan of RMB8.5 million will continue to bear interest at 3% per annum from 1 January 2026, payable quarterly, and remains secured by a pledge over two invention patents owned by Guangzhou Taili; the transaction is classified as a connected transaction under Hong Kong Listing Rules, triggering announcement and reporting obligations but remaining exempt from circular and independent shareholders’ approval requirements due to its size, signalling limited shareholder approval risk while formalizing continued financial support to related parties.

The most recent analyst rating on (HK:0690) stock is a Hold with a HK$0.12 price target. To see the full list of analyst forecasts on Uni-Bio Science Group Ltd. stock, see the HK:0690 Stock Forecast page.